A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Cabozantinib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Bone metastases
- Focus Therapeutic Use
- 25 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2020.
- 25 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 13 Apr 2017 Status changed from recruiting to active, no longer recruiting.